Brief: Moleculin’S Miracle R/R Aml Trial Reports Positive Interim Data With 37% Blinded Crc In Venetoclax-Failed Patients
31/07/2026 13:11
BRIEF-Moleculin’S Miracle R/R Aml Trial Reports Positive Interim Data With 37% Blinded Crc In Venetoclax-Failed Patients July 31 (Reuters) - Moleculin Biotech Inc MBRX.O:
MOLECULIN’S MIRACLE R/R AML TRIAL REPORTS POSITIVE INTERIM DATA WITH 37% BLINDED CRC IN VENETOCLAX-FAILED PATIENTS
MOLECULIN BIOTECH - NO EVIDENCE OF CARDIOTOXICITY OBSERVED WITH ANNAMYCIN IN MIRACLE TRIAL
MOLECULIN BIOTECH - MIRACLE TRIAL PART A FINAL TREATMENT EXPECTED SEPTEMBER 2026; UNBLINDED RESULTS DECEMBER 2026–FEBRUARY 2027
Source text: ID:nGNX1vjyS
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM